Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 3:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,740 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Platinum-based chemotherapy Clear all
Active, not recruiting Phase 2 Interventional

Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma

NCT01025089
View directory record Official record
Conditions
Thymoma, Thymic Carcinoma, Clinical Masaoka Stage II to IVA
Interventions
Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
8
States / cities
Duarte, California • Basking Ridge, New Jersey • Commack, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 4, 2026, 3:45 AM EDT
Terminated Early Phase 1 Interventional Results available

Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma

NCT02212574
View directory record Official record
Conditions
Medulloblastoma
Interventions
Lomustine, Vincristine, Cisplatin, Cyclophosphamide, Mesna
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
3 Years to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
16
States / cities
Phoenix, Arizona • Aurora, Colorado • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 4, 2026, 3:45 AM EDT
Recruiting Phase 1 Interventional

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

NCT05285358
View directory record Official record
Conditions
Distal Bile Duct Adenocarcinoma, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Stage IVB Gallbladder Cancer AJCC v8
Interventions
Cisplatin, Gemcitabine, Nab-paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 4, 2026, 3:45 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

NCT02041533
View directory record Official record
Conditions
Stage IV or Recurrent Non-Small Cell Lung Cancer
Interventions
Nivolumab, Gemcitabine, Cisplatin, Carboplatin, Paclitaxel, Pemetrexed
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
36
States / cities
Mobile, Alabama • Gilbert, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Sep 4, 2026, 3:45 AM EDT
Recruiting Phase 2 Interventional

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

NCT06001658
View directory record Official record
Conditions
Billiary Track Cancer
Interventions
Gemcitabine, Cisplatin, Pembrolizumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 4, 2026, 3:45 AM EDT
Completed Phase 3 Interventional Results available

Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer

NCT03349710
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Nivolumab, Cetuximab, Cisplatin, Radiotherapy
Biological · Drug · Radiation
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Anniston, Alabama • Goodyear, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2021 · Synced Sep 4, 2026, 3:45 AM EDT
Completed Phase 3 Interventional Results available

LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

NCT01345682
View directory record Official record
Conditions
Head and Neck Neoplasms, Carcinoma, Squamous Cell
Interventions
Afatinib, Methotrexate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
8
States / cities
Harvey, Illinois • Peoria, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Sep 4, 2026, 3:45 AM EDT
Terminated Phase 2 Interventional Results available

RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy

NCT02452970
View directory record Official record
Conditions
Cholangiocarcinoma
Interventions
RRx-001, Gemcitabine and cisplatin
Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 4, 2026, 3:45 AM EDT
Completed Phase 1 Interventional

Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma

NCT00970996
View directory record Official record
Conditions
Melanoma
Interventions
Temozolomide, Abraxane, Cisplatin, Interleukin-2, Interferon alpha 2b
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Sep 4, 2026, 3:45 AM EDT
Not listed Phase 2 Interventional

International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel

NCT02051868
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Anus
Interventions
Cisplatin, 5-Fluorouracil (5-FU), Carboplatin, Paclitaxel
Drug
Lead sponsor
Royal Marsden NHS Foundation Trust
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 4, 2026, 3:45 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma

NCT00302003
View directory record Official record
Conditions
Childhood Favorable Prognosis Hodgkin Lymphoma, Childhood Lymphocyte Depletion Hodgkin Lymphoma, Childhood Mixed Cellularity Hodgkin Lymphoma, Childhood Nodular Sclerosis Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma
Interventions
radiation therapy, doxorubicin hydrochloride, vincristine sulfate, prednisone, cyclophosphamide, ifosfamide, vinorelbine tartrate, dexamethasone, etoposide phosphate, cisplatin, cytarabine, filgrastim
Radiation · Drug · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Sep 4, 2026, 3:45 AM EDT
Completed Phase 1Phase 2 Interventional

QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma

NCT01029873
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Cisplatin, ALT-801
Drug · Biological
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Sep 4, 2026, 3:45 AM EDT
Completed Phase 3 Interventional Results available

Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer

NCT00686959
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pemetrexed, Cisplatin, Etoposide, Vinorelbine, Paclitaxel, Carboplatin, Thoracic Radiation Therapy (TRT)
Drug · Radiation
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
50
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Sep 4, 2026, 3:45 AM EDT
Completed Phase 1Phase 2 Interventional

Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer

NCT00003379
View directory record Official record
Conditions
Cervical Cancer
Interventions
cisplatin, paclitaxel, brachytherapy, radiation therapy
Drug · Radiation
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
31
States / cities
Phoenix, Arizona • Newark, Delaware • Chicago, Illinois + 26 more
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced Sep 4, 2026, 3:45 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

NCT00003691
View directory record Official record
Conditions
Endometrial Cancer
Interventions
filgrastim, cisplatin, doxorubicin hydrochloride, paclitaxel
Biological · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2013 · Synced Sep 4, 2026, 3:45 AM EDT
Completed Phase 2 Interventional

Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors

NCT00984997
View directory record Official record
Conditions
Lung Cancer
Interventions
Surgery, Chest Irradiation, Cisplatin, Etoposide, Prophylactic Cranial Irradiation
Procedure · Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Sep 4, 2026, 3:45 AM EDT
Withdrawn Phase 1 Interventional

Neoadjuvant Therapy in Biliary Adenocarcinoma

NCT04480190
View directory record Official record
Conditions
Cholangiocarcinoma, Biliary Cancer
Interventions
Gemcitabine, Cisplatin, Fluorouracil, Short course ChemoRT
Drug · Radiation
Lead sponsor
Jordan Kharofa
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 4, 2026, 3:45 AM EDT
Completed Phase 3 Interventional Results available

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET

NCT00392327
View directory record Official record
Conditions
Anaplastic Medulloblastoma, Medulloblastoma
Interventions
Biospecimen Collection, Carboplatin, Cisplatin, Cyclophosphamide, Filgrastim, Isotretinoin, Lumbar Puncture, Magnetic Resonance Imaging, Quality-of-Life Assessment, Radiation Therapy, Vincristine Sulfate
Procedure · Drug · Biological + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 22 Years
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2026
U.S. locations
170
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 4, 2026, 3:45 AM EDT
Completed Phase 2 Interventional Results available

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

NCT03786783
View directory record Official record
Conditions
Ganglioneuroblastoma, High Risk Neuroblastoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Dexrazoxane, Dinutuximab, Doxorubicin, Etoposide, External Beam Radiation Therapy, Isotretinoin, Melphalan, Sargramostim, Thiotepa, Topotecan, Vincristine
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 4, 2026, 3:45 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy

NCT01859741
View directory record Official record
Conditions
Stage IV Small Cell Lung Cancer
Interventions
OMP-59R5, Etoposide, Placebo, Cisplatin or Carboplatin
Drug
Lead sponsor
OncoMed Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
35
States / cities
Rogers, Arkansas • Los Angeles, California • Denver, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 4, 2026, 3:45 AM EDT
Recruiting Phase 2 Interventional

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

NCT06064097
View directory record Official record
Conditions
Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Chest Radiography, Cisplatin, Computed Tomography, Echocardiography Test, Electronic Health Record Review, Fluciclovine F18, Gemcitabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, X-Ray Imaging
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
76
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 4, 2026, 3:45 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

NCT00336024
View directory record Official record
Conditions
Anaplastic Medulloblastoma, Medulloblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Leucovorin Calcium, Methotrexate, Quality-of-Life Assessment, Thiotepa, Vincristine Sulfate
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 2 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
129
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 100 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 4, 2026, 3:45 AM EDT
Active, not recruiting Phase 2 Interventional

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

NCT04379596
View directory record Official record
Conditions
Gastric Cancer
Interventions
Fluorouracil (5-FU), Capecitabine, Durvalumab, Oxaliplatin, Trastuzumab, Trastuzumab deruxtecan, Cisplatin, Pembrolizumab, Volrustomig, Rilvegostomig
Drug · Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 4, 2026, 3:45 AM EDT
Terminated Early Phase 1 Interventional

Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients

NCT04213794
View directory record Official record
Conditions
Malignant Abdominal Neoplasm, Malignant Pelvic Neoplasm, Recurrent Colon Carcinoma, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Gastric Carcinoma, Recurrent Liposarcoma, Recurrent Malignant Mesothelioma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Rectal Carcinoma, Recurrent Rhabdomyosarcoma, Recurrent Sarcoma, Refractory Colon Carcinoma, Refractory Desmoplastic Small Round Cell Tumor, Refractory Fallopian Tube Carcinoma, Refractory Gastric Carcinoma, Refractory Liposarcoma, Refractory Malignant Mesothelioma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma, Refractory Rectal Carcinoma, Refractory Rhabdomyosarcoma, Refractory Sarcoma, Resectable Liposarcoma, Resectable Malignant Mesothelioma, Resectable Sarcoma
Interventions
Cisplatin, Cytoreductive Surgery, Doxorubicin, Hyperthermic Intraperitoneal Chemotherapy, Sodium Thiosulfate, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Biospecimen Collection
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Year to 25 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Sep 4, 2026, 3:45 AM EDT